A Phase III, randomised study of aspirin and esomeprazole chemoprevention in Barrett's metaplasia.

Trial Results

The results of the AspECT trial have now been published in The Lancet. Please find a lay summary of the results HERE

To view the full journal article online, please click HERE

If you wish to discuss the results, please contact your GP or your study doctor.

Study Objectives

To assess whether intervention with aspirin and/or high dose PPI therapy results in decreased mortality or conversion rate from Barrett’s metaplasia to adenocarcinoma or high grade dysplasia.